Clinical trial
Cognition, Functioning and Quality of Life
NCT00182442 · Hamilton Health Sciences Corporation, Other · Completed
Key facts
| NCT number | NCT00182442 |
|---|---|
| Title | Cognition, Functioning and Quality of Life |
| Official title | A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine & Quetiapine |
| Enrollment | 80 |
| Start date | Oct 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Oct 11, 2006 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: